单价2型口服脊髓灰质炎疫苗(mOPV2)的现场管理:干预措施与经验教训
本文回顾2016年4月至5月三价口服脊髓灰质炎疫苗(tOPV) switched to 二价口服脊髓灰质炎疫苗(bOPV)后,mOPV2用于应对循环疫苗衍生2型脊髓灰质炎病毒(cVDPV2)疫情时的现场管理表现。文章总结各国在疫苗管理各环节的差距与经验教训,指出疫苗 accountability 存在重大缺口,大量疫苗瓶去向不明,增加了新的VDPV2出现的风险。
要点
- 各国在评估的各活动领域表现差异显著,疫苗accountability方面存在重大缺口。
- 许多情况下大量疫苗瓶去向不明,增加了进一步出现VDPV2的风险。
核心结论
- 各国在mOPV2疫苗管理各评估领域表现差异显著,疫苗accountability存在重大缺口,许多情况下大量疫苗瓶去向不明,增加了进一步出现VDPV2的风险。
- 实施初期对mOPV2疫苗管理关注不足,加强mOPV2疫苗管理应成为公共卫生规划和各国在未来VDPV2应对及最终完全停用OPV相关活动中考虑和调整的优先事项。
- 这些经验也可推广到其他需要严格库存管理和containment措施的疫苗。
研究设计与样本
- 本文考察2016年4月至5月tOPV to bOPV switch后用于各类疫情应对的mOPV2疫苗管理表现。
主要发现
- 各国在评估的各活动领域表现差异显著。
- 疫苗accountability方面存在重大缺口,许多情况下大量疫苗瓶去向不明,增加了进一步出现VDPV2的风险。
- 实施初期对mOPV2疫苗管理关注不足。
临床怎么用
- 文章提出,加强mOPV2疫苗管理应成为公共卫生规划和各国在未来VDPV2应对及最终完全停用OPV相关活动中考虑和调整的优先事项。
- 文章提出,这些经验也可推广到其他需要严格库存管理和containment措施的疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The polio endgame strategy calls for ending the use of and removal of all Sabin vaccines globally given the risks of generation and spread of cVDPVs. With the successful eradication of wild poliovirus type 2 in 2015, the process of removing type 2 Sabin vaccines began with the switch from tOPV to bOPV across national vaccination programs. Following the tOPV to bOPV switch in April/May 2016, monovalent type 2 OPV (mOPV2) has been put into use in response to detected cVDPV2 polioviruses outbreaks. Between 31 May 2016 and 30 Jun 2020, 453 million doses of mOPV2 were provided to 21 countries to conduct 235 campaigns to respond to cVDPV2 outbreaks and high-risk events. However, the use of this vaccine paradoxically reintroduces live attenuated type 2 poliovirus into the populations and the environment, therefore, poses a risk for the emergence of new VDPV2s. Thus, it is critical to carefully and appropriately manage all in-country mOPV2 stocks utilized in outbreak response to minimize this risk. In this article, we examine the performance of mOPV2 vaccine management utilized for various outbreak responses after the switch.We present the major challenges faced and the lessons learned, to improve technical guidance and future response activities. Performance varied significantly across countries in terms of each of the activity areas evaluated. There were major gaps, especially in terms of vaccine accountability, and in many instances large numbers of vials went unaccounted presenting additional risk for further VDPV2 emergences. We have shown that especially at the beginning of implementation, insufficient attention has been given to mOPV2 vaccine management. Enhanced focus on mOPV2 vaccine management in line with the lessons learned presented in this paper should be a priority for public health programs and countries to consider and adapt in future VDPV2 responses as well as potential future activities associated with eventual complete withdrawal & cessation of OPV.These experiences can also be extended to other vaccines for which strict stock management and containment measures are required.
引用
- Afsar A, Mallya A, Mohammed AAG, et al. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned. Vaccine. 2023. PMID: 36642630. doi:10.1016/j.vaccine.2022.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。